CN104857180B - Composition for resisting fatigue and improving immunity and preparation method and application thereof - Google Patents
Composition for resisting fatigue and improving immunity and preparation method and application thereof Download PDFInfo
- Publication number
- CN104857180B CN104857180B CN201510286099.0A CN201510286099A CN104857180B CN 104857180 B CN104857180 B CN 104857180B CN 201510286099 A CN201510286099 A CN 201510286099A CN 104857180 B CN104857180 B CN 104857180B
- Authority
- CN
- China
- Prior art keywords
- composition
- fatigue
- coenzyme
- grape seed
- seed extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 75
- 230000036039 immunity Effects 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 229940087603 grape seed extract Drugs 0.000 claims abstract description 41
- 235000002532 grape seed extract Nutrition 0.000 claims abstract description 41
- 239000001717 vitis vinifera seed extract Substances 0.000 claims abstract description 41
- 230000002929 anti-fatigue Effects 0.000 claims abstract description 33
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims abstract description 32
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 29
- 229940110767 coenzyme Q10 Drugs 0.000 claims abstract description 28
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 28
- 239000003814 drug Substances 0.000 claims abstract description 8
- 230000002708 enhancing effect Effects 0.000 claims abstract description 6
- 235000013305 food Nutrition 0.000 claims abstract description 4
- 230000036541 health Effects 0.000 claims abstract description 4
- 235000013361 beverage Nutrition 0.000 claims abstract 3
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 claims description 31
- 239000008187 granular material Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 8
- 239000007901 soft capsule Substances 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 239000007902 hard capsule Substances 0.000 claims description 3
- 239000003094 microcapsule Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims 4
- 239000002417 nutraceutical Substances 0.000 claims 2
- 235000021436 nutraceutical agent Nutrition 0.000 claims 2
- 238000002474 experimental method Methods 0.000 abstract description 33
- 230000000694 effects Effects 0.000 abstract description 26
- 239000003963 antioxidant agent Substances 0.000 abstract description 11
- 230000003078 antioxidant effect Effects 0.000 abstract description 11
- 235000006708 antioxidants Nutrition 0.000 abstract description 11
- 239000000126 substance Substances 0.000 abstract description 10
- 241001465754 Metazoa Species 0.000 abstract description 5
- 238000012216 screening Methods 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 4
- 230000006870 function Effects 0.000 abstract description 4
- 238000005259 measurement Methods 0.000 abstract description 4
- 231100000957 no side effect Toxicity 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 26
- 206010016256 fatigue Diseases 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 206010020751 Hypersensitivity Diseases 0.000 description 7
- 210000000628 antibody-producing cell Anatomy 0.000 description 7
- 230000003111 delayed effect Effects 0.000 description 7
- 102000019197 Superoxide Dismutase Human genes 0.000 description 6
- 108010012715 Superoxide dismutase Proteins 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 6
- 239000005515 coenzyme Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 244000269722 Thea sinensis Species 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 229940118019 malondialdehyde Drugs 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 description 4
- 235000013824 polyphenols Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 230000009182 swimming Effects 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 108010063907 Glutathione Reductase Proteins 0.000 description 3
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000241413 Propolis Species 0.000 description 3
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 3
- 208000030961 allergic reaction Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000009661 fatigue test Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 210000000548 hind-foot Anatomy 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 150000004804 polysaccharides Chemical class 0.000 description 3
- 229940069949 propolis Drugs 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 235000020712 soy bean extract Nutrition 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000264279 Sargassum fusiforme Species 0.000 description 2
- 235000010841 Silybum marianum Nutrition 0.000 description 2
- 244000272459 Silybum marianum Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- -1 quinone compound Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000035806 respiratory chain Effects 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000036624 brainpower Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229940002508 ginger extract Drugs 0.000 description 1
- 235000020708 ginger extract Nutrition 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N para-benzoquinone Natural products O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- RNUCUWWMTTWKAH-JLHYYAGUSA-N ubiquinol-2 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1OC RNUCUWWMTTWKAH-JLHYYAGUSA-N 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a composition for resisting fatigue and improving immunity and a preparation method and application thereof, belonging to the field of anti-fatigue health care products. The composition for resisting fatigue and improving immunity comprises the following components: coenzyme Q10 and grape seed extract. According to the invention, coenzyme Q10 is combined with various natural antioxidant substances, the anti-fatigue activity of different compositions is investigated, and finally, the composition consisting of coenzyme Q10 and grape seed extract is found to have the most remarkable anti-fatigue activity. The invention further determines the optimal dosage ratio of the coenzyme Q10 and the grape seed extract through a dosage screening experiment. Animal experiments and biochemical index measurement results show that the composition has extremely obvious functions of resisting fatigue activity and enhancing immunity. The composition can be used for preparing medicines, health-care products, beverages or foods and the like for resisting fatigue and improving immunity, and has good safety and no side effect.
Description
Technical Field
The invention relates to a composition for resisting fatigue and improving immunity, in particular to a composition which takes coenzyme Q10 and grape seed extract as active ingredients and has the effects of resisting fatigue and improving immunity of a human body, and also relates to a preparation method and application of the composition, belonging to the field of health care products for resisting fatigue and improving immunity.
Background
Coenzyme Q10 (CoQ), also known as ubiquinone (UQ, Q), is a coenzyme loosely bound to proteins in the respiratory chain, is a fat-soluble quinone compound widely present in the body, and plays an important role in proton translocation and electron transfer in the respiratory chain of the human body. Coenzyme Q10 acts as an activator of cellular metabolism and cellular respiration and is also an important antioxidant and non-specific immunopotentiator. Coenzyme Q10 has two forms, oxidized form and reduced form. After the oxidized coenzyme Q10 enters the human body, the dehydrogenase needs to be converted once again, and the converted form is called reduced coenzyme Q10, which is more directly utilized by the human body, so that the reduced coenzyme Q10 has more direct action in the metabolism of the human body compared with the oxidized coenzyme Q10.
Fatigue is a complex physiological and biochemical change process of an organism and is a normal physiological phenomenon which is inevitably generated when human brain power or physical strength reaches a certain stage. The occurrence of fatigue can cause the reduction of the exercise capacity, the reduction of the working efficiency and the increase of error accidents; if the fatigue can not be recovered in time after the occurrence of the fatigue, the fatigue can be gradually accumulated, the overstrain syndrome, the chronic fatigue syndrome and the like can also be caused, so that the endocrine disturbance, the immunity decline and even the organic lesion of the organism can be caused, and the fatigue becomes an important factor for threatening the health of human beings.
Therefore, the development of the composition with definite anti-fatigue and immunity-improving effects has important market value and social significance.
Disclosure of Invention
The invention aims to solve the technical problem of providing the composition for resisting fatigue and improving immunity, which takes the coenzyme Q10 and the grape seed extract as active ingredients and has obvious effects of resisting fatigue and improving the immunity of a human body.
In order to solve the technical problems, the technical scheme adopted by the invention is as follows:
the invention firstly discloses a composition for resisting fatigue and improving immunity, which comprises the following components: coenzyme Q10 and grape seed extract.
Coenzyme Q10 by mass ratio: grape seed extract ═ (1-15): (1-20); preferably, coenzyme Q10: grape seed extract ═ 1: 11-15; most preferably, coenzyme Q10: grape seed extract ═ 1: 13.
the coenzyme Q10 is reduced coenzyme Q10; compared with oxidized coenzyme Q10, reduced coenzyme Q10 has higher absorptivity and bioavailability, and can reach the same in vivo level by only needing smaller dose.
The reduced coenzyme Q10 can be purchased commercially, synthesized chemically, or extracted and separated from animals and plants, and the extraction method is well known to those skilled in the art. The grape seed extract may be purchased commercially or extracted from grape seeds by methods well known to those skilled in the art.
The invention combines reduced coenzyme Q10 with a plurality of natural antioxidant substances, namely tea polyphenol, vitamin C, vitamin E, soybean extract, grape seed extract and the like according to a certain proportion, carries out a mouse weight swimming experiment, and investigates the anti-fatigue activity of different compositions. The results show that the combination of the reduced coenzyme Q10 and different natural antioxidant substances has different degrees of anti-fatigue effect. The composition of the reduced coenzyme Q10 and the grape seed extract has very obvious anti-fatigue activity, the difference between the endurance time of a mouse and a blank control group is very obvious (P is less than or equal to 0.001), and the anti-fatigue activity is obviously superior to the combination of the reduced coenzyme Q10 and other natural antioxidant substances.
On the basis of screening out the reduced coenzyme Q10 and the grape seed extract as the components of the composition, the invention further optimizes the dosage and the proportion of the reduced coenzyme Q10 and the grape seed extract. Screening reduced coenzyme Q10 and a grape seed extract according to a mass ratio of 1: the composition consisting of 13 has extremely obvious anti-fatigue activity, the difference between the endurance time of the mice in the group and the blank control group is extremely obvious (P is less than or equal to 0.001), and the anti-fatigue activity is obviously superior to that of other dosage combinations.
The invention determines the biochemical indexes of fatigue resistance, and the results show that the reduced coenzyme Q10 and the grape seed extract are mixed according to the mass ratio of 1: 13 the serum lactic acid, urea nitrogen and MDA levels of the composition are significantly lower than those of the blank control group, while the levels of superoxide dismutase (SOD), glutathione reductase (GSH-PX) and liver glycogen are significantly higher than those of the blank control group. From the viewpoint of biochemical indexes, it is also proved that the reduced coenzyme Q10 and the grape seed extract are mixed according to the mass ratio of 1: 13 has extremely remarkable anti-fatigue activity.
The composition has the effects of resisting fatigue and enhancing immunity. The experimental result of detecting the influence of the composition consisting of the reduced coenzyme Q10 and the grape seed extract in different mass ratios on the delayed type allergy (DTH) and the number of antibody-producing cells of mice shows that the reduced coenzyme Q10 and the grape seed extract are mixed according to the mass ratio of 1: 13 can also obviously improve the delayed type allergic reaction capability and the number of antibody generating cells (P is less than or equal to 0.05) of the mice, which indicates that the composition also has very good function of enhancing the immunity.
On the basis of the composition for resisting fatigue and improving immunity, the composition can be added with proper auxiliary materials or carriers to prepare medicines, health-care products, drinks or foods for resisting fatigue and improving immunity; wherein the dosage form of the medicine or the health-care product comprises: tablet, granule, pill, emulsion, granule, soft capsule, hard capsule or microcapsule.
The carrier or the auxiliary material refers to a carrier or an auxiliary material which is conventional in the pharmaceutical field, such as: diluents, disintegrants, lubricants, excipients, binders, glidants, fillers, surfactants, and the like; in addition, other adjuvants such as flavoring agents and sweeteners may also be added to the composition.
The diluent may be one or more ingredients that increase the weight and volume of the tablet; common diluents include lactose, starch, pregelatinized starch, microcrystalline cellulose, sorbitol, mannitol, and inorganic calcium salts. The most common of them are lactose, starch, microcrystalline cellulose.
The disintegrant can be one or more of crosslinked polyvinylpyrrolidone (with a total weight ratio of 2-6%), crosslinked sodium carboxymethylcellulose (with a total weight ratio of 2-6%), alginic acid (with a total weight ratio of 2-5%), and microcrystalline cellulose (with a total weight ratio of 5-15%). Wherein the preferred ratio is crosslinked polyvinylpyrrolidone (2-7% by weight) and crosslinked sodium carboxymethylcellulose (2-6% by weight). Most preferably crosslinked polyvinylpyrrolidone (in a ratio of 2-6% by weight relative to the total weight).
The lubricant comprises one or a mixture of stearic acid, sodium stearate, magnesium stearate, calcium stearate, polyethylene glycol, talcum powder and hydrogenated vegetable oil. Magnesium stearate is most preferred. The amount of the lubricant is in the range of 0.10 to 1% (by total weight), and is generally 0.25 to 0.75%, and preferably 0.5 to 0.7%.
The binder may be one or more ingredients that facilitate granulation. It may be starch slurry (10-30% by weight of the total binder), hydroxypropyl methylcellulose (2-5% by weight of the total binder), polyvinylpyrrolidone (2-20% by weight of the total binder), preferably ethanol aqueous solution of polyvinylpyrrolidone, and most preferably 50% ethanol aqueous solution of polyvinylpyrrolidone.
The glidant can be one or a mixture of more of superfine silica gel powder, talcum powder and magnesium trisilicate.
The surfactant may be one or more components that improve wetting and increase drug dissolution. Sodium lauryl sulfate is often used (the usual range is 0.2-6% by weight, based on the total weight).
Compared with the prior art, the technical scheme of the invention has the following beneficial effects:
the invention combines the reduced coenzyme Q10 with a plurality of natural antioxidant substances, and screens out the anti-fatigue and immunity-improving composition consisting of the reduced coenzyme Q10 and the grape seed extract, the combination of the two has obvious synergistic effect, and the combination of the two according to a specific dosage proportion can obtain extremely obvious anti-fatigue and immunity-improving effects, and the invention has no adverse reaction and good safety.
Detailed Description
The invention will be further described with reference to specific embodiments, and the advantages and features of the invention will become apparent as the description proceeds. It is to be understood that the described embodiments are exemplary only and are not limiting upon the scope of the invention. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention, and that such changes and modifications may be within the scope of the invention.
1. Raw materials
Reduced coenzyme Q10 was purchased from Western Anwei Olympic Biotech Ltd; the grape seed extract is purchased from Xianchang Yue plant chemical Co., Ltd; tea polyphenols are purchased from Wuxi Lubao biological products, Inc.; vitamin C and vitamin E were purchased from Guangzhou Qiyun Biotech, Inc.; propolis is purchased from Changsha Firpole plants GmbH; the sargassum fusiforme polysaccharide is prepared by a method of a reference document (Zhoujing. extraction, separation and activity research of natural antioxidant substances. 2008. Zhejiang university. Master academic thesis); the ginseng extract is purchased from Shaanxi brocade bioengineering GmbH; the soybean extract, the silybum marianum extract and the ginger extract are purchased from Shanxi Longfu biochemical engineering Co., Ltd.
EXAMPLE 1 preparation of anti-fatigue and Immunity-enhancing composition
Weighing the following raw materials (g): reduced coenzyme Q101 and grape seed extract 13 are evenly mixed to obtain the grape seed extract.
EXAMPLE 2 preparation of anti-fatigue and Immunity-enhancing composition
Weighing the following raw materials (g): reduced coenzyme Q101 and grape seed extract 11 are evenly mixed to obtain the grape seed extract.
EXAMPLE 3 preparation of anti-fatigue and Immunity-enhancing composition
Weighing the following raw materials (g): reduced coenzyme Q101 and grape seed extract 15 are evenly mixed to obtain the grape seed extract.
EXAMPLE 4 preparation of anti-fatigue and Immunity-enhancing composition
Weighing the following raw materials (g): reduced coenzyme Q101 and grape seed extract 20 are evenly mixed to obtain the grape seed extract.
EXAMPLE 5 preparation of anti-fatigue and Immunity-enhancing composition
Weighing the following raw materials (g): reducing coenzyme Q1015 and grape seed extract 1, and mixing uniformly to obtain the final product.
EXAMPLE 6 preparation of Soft capsules
Uniformly mixing 200g of glycerol, 320g of gelatin, 450g of purified water and 2g of pigment, heating for dissolving, defoaming in vacuum, standing and preserving heat to obtain a gelatin solution; 60g of the composition prepared in the example 1 is heated to be dissolved, then mixed with the gelatin melting liquid to be made into pills according to the soft capsule bundling process, and the soft capsules are obtained after shaping, washing, drying and picking up the pills.
EXAMPLE 7 preparation of tablets
15g of the composition prepared in the embodiment 2 is added with 15g of starch, evenly mixed, then evenly mixed with 30 g of dextrin, and added with a proper amount of ethanol (50%) to prepare a soft material; granulating through a 16-mesh nylon sieve, drying at 60 ℃, sieving the dried granules again through a 16-mesh sieve for finishing granules, adding 5g of magnesium stearate, uniformly mixing and tabletting.
EXAMPLE 8 preparation of granules
Taking 3 g of the composition prepared in example 3, mixing with 5g of microcrystalline cellulose, 3 g of lactose and 1g of croscarmellose sodium, preparing a soft material by taking 3% povidone-ethanol solution (with the concentration of 50%) as a binding agent, sieving with a 40-mesh sieve, granulating, drying at 60 ℃, sieving with a 30-mesh sieve, and finishing granules to obtain the granules.
Experimental example 1 composition screening experiment for anti-fatigue and immunity improvement
1. Experimental methods
1.1 formulation of the composition
Respectively combining reduced coenzyme Q10 with natural antioxidant substances such as tea polyphenols, vitamin C, vitamin E, propolis, herba Silybi Mariani extract, Cyrtymenia Sparsa polysaccharide, semen glycines extract, grape seed extract, Ginseng radix extract, and rhizoma Zingiberis recens extract, and mixing well to obtain the composition. Wherein the mass ratio of the reduced coenzyme Q10 to the natural antioxidant substances is 1: 10.
1.2 animal groups and types and dosages of administration
Male ICR mice (20 ± 1g) at 7 weeks of age (beijing weitonglihua laboratory animal technology ltd), laboratory animal certification No.: SCXK (Jing) 2012 and 0001. Mice were randomly divided into blank control groups and experiment 1-10 groups of 12 mice each. The test drug is administrated to the mice by intragastric administration once a day, the dose is 0.15g/Kg, and the mice are intragastric administered for 30 days.
Blank control group: perfusing stomach with normal saline;
experiment 1 group: administering a composition consisting of reduced coenzyme Q10 and tea polyphenol for intragastric administration;
experiment 2 group: administering a composition of coenzyme Q10 and vitamin C, and performing intragastric administration;
experiment 3 groups: administering a composition of coenzyme Q10 and vitamin E for intragastric administration;
experiment 4 groups: administering coenzyme Q10 and propolis composition, and intragastrically;
experiment 5 group: administering a composition consisting of coenzyme Q10 and Silybum marianum extract, and intragastrically;
experiment 6 groups: administering a composition consisting of coenzyme Q10 and sargassum fusiforme polysaccharide, and performing intragastric administration;
experiment 7 groups: administering a composition comprising coenzyme Q10 and soybean extract, and intragastrically;
experiment 8 groups: administering a composition comprising coenzyme Q10 and grape seed extract, and intragastrically;
experiment 9 groups: administering coenzyme Q10 and Ginseng radix extract composition, and intragastrically;
experiment 10 groups: administering coenzyme Q10 and rhizoma Zingiberis recens extract composition, and intragastric irrigating.
1.3 mouse weight bearing swimming experiment
The detection method comprises the following steps: after 30 minutes of the last administration, randomly extracting 1 mouse from each group with a lead skin with the weight of 3 percent corresponding to the tail part of the mouse, putting the mice into water to start timing, and recording the first sinking time and exhaustion time of the mice till the exhaustion of the mice is finished, wherein the difference of the two times represents the endurance capacity of the mice;
detecting a container: adopting a bucket with the diameter of 43cm and the height of 40cm, wherein the water level is 25cm, the water temperature is 25 +/-1 ℃, and 4 buckets are used; detection standard: the first sinking standard is that the nose tip of the mouse firstly sinks below the water surface; the exhaustion standard is that the mice do not float upwards after sinking underwater for 10 s.
1.4 statistical methods
The data processing is carried out by adopting SPSS statistical analysis software, and all the data are calculated as the mean value plus or minus standard error
Indicated, differences between groups were treated with One-way ANOVA.
2. Results of the experiment
The experimental results are shown in Table 1, and it can be seen that the reduced coenzyme Q10 has different degrees of anti-fatigue effects when combined with different natural antioxidant substances. The composition of the experiment 8 group, namely the reduced coenzyme Q10 and the grape seed extract, has very obvious anti-fatigue activity, the endurance time of the mice in the group is very different from that of a blank control group (P is less than or equal to 0.001), and the anti-fatigue activity is obviously superior to that of the reduced coenzyme Q10 and other natural antioxidant substances.
TABLE 1 anti-fatigue test results for different compositions
P ≦ 0.05, statistically different from the blank group;
p ≦ 0.01, statistically significantly different from the blank group;
indicates P ≦ 0.001, with a very significant statistical difference compared to the blank group.
Experimental example 2 screening experiment for formula dosage of composition for anti-fatigue and enhancing immunity
1. Experimental methods
1.1 formulation of the composition
The invention combines reduced coenzyme Q10 and grape seed extract according to different dosage proportions on the basis of experimental example 1 (table 2), and carries out mouse swimming-bearing experiments according to the method of experimental example 1.
TABLE 2 different ratios of the compositions
2. Results of the experiment
The experimental results are shown in Table 3, and it can be seen that different combinations of reduced coenzyme Q10 and grape seed extract have different degrees of anti-fatigue effects. Wherein the mass ratio of reduced coenzyme Q10 to grape seed extract is 1: the composition consisting of 13 has obvious anti-fatigue activity, the difference between the endurance time of the mice in the group and the blank control group is very obvious (P is less than or equal to 0.001), and the anti-fatigue activity is obviously superior to that of the combination with other dosage.
TABLE 3 anti-fatigue test results for different compositions
P ≦ 0.01, statistically significantly different from the blank group;
indicates P ≦ 0.001, with a very significant statistical difference compared to the blank group.
Experimental example 3 measurement experiment of biochemical indexes of fatigue resistance
1. Experimental methods
After the mice in experiment example 2 were subjected to exhaustive swimming test for 10 minutes, the mice in the blank control group and experiment 6 group were immediately picked up to take blood from the eyeballs, and the liver tissues were dissected and taken out. Standing the blood in a refrigerator at 4 deg.C overnight, centrifuging at 3000r/min for 10min the next day, and collecting serum; the liver tissue is stored at-80 deg.C for use.
And (3) determination of biochemical indexes: serum was used for the determination of blood lactate and urea nitrogen, and liver was used for the determination of liver glycogen, Malondialdehyde (MDA), superoxide dismutase (SOD), and glutathione reductase (GSH-PX). All biochemical kits are provided by Nanjing institute of bioengineering, and the determination method is carried out according to the kit instruction.
2. Results of the experiment
As can be seen from table 4, reduced coenzyme Q10 and grape seed extract were mixed in a mass ratio of 1: 13, the serum lactic acid, urea nitrogen and MDA levels were significantly lower than those of the placebo group, while the superoxide dismutase (SOD), glutathione reductase (GSH-PX) and liver glycogen levels were significantly higher than those of the placebo group. From the viewpoint of biochemical indexes, it is also proved that the reduced coenzyme Q10 and the grape seed extract are mixed according to the mass ratio of 1: 13 has extremely remarkable anti-fatigue activity.
TABLE 4 Biochemical index of anti-fatigue test results
P ≦ 0.05, statistically different from the blank group;
p ≦ 0.01, statistically significant compared to the blank group.
Experimental example 4 detection of immunity-enhancing function of composition for anti-fatigue and enhancing immunity
1. Experimental methods
Reduced coenzyme Q10 and grape seed extract were used to prepare compositions according to Table 2 of Experimental example 2, and mice were randomly divided into a blank control group and experiment groups 1-14, each group containing 10 mice, and they were gavaged once daily for 30 days according to the method and dose of Experimental example 1.
1.1 delayed type allergic reaction (DTH) (foot-cast thickening method)
After the mice were continuously given for 30 days, the plantar thickness of the left hind foot was measured 4 days after the mice were intraperitoneally injected with 2% (v/v) SRBC (0.2m 1/per mouse) for sensitization, and then the plantar thickness of the left hind foot was measured 24 hours after the injection by subcutaneously injecting 20% (v/v) SRBC (20. mu.l/per mouse) at the measurement site, and the thickness of the plantar portion of the left hind foot was measured three times at the same site and averaged. The degree of DTH is expressed as the difference in thickness of the plantar region of the foot (degree of swelling of the plantar region) before and after the attack.
1.2 measurement of antibody-producing cells (Jerne modified slide method)
After the mice are continuously given samples for 30 days, sheep blood is taken and washed 3 times by physiological saline, each time, the sheep blood is centrifuged (2000r/min) for l0min, the overstocked SRBC is prepared into 2 percent (v/v) cell suspension by the physiological saline, and each mouse is injected with 0.2m1 in the abdominal cavity. After 4 days, the mice were sacrificed, the spleen was taken, gently ground, made into a cell suspension using Hank's solution, sieved with a 200-mesh sieve, washed, centrifuged 2 times, and finally suspended in 8m1Hank's solution, the cells were counted, and the cell concentration was adjusted to 5X 106One per ml. Heating to dissolve surface layer culture medium, mixing with equal amount of 2 times concentration of Hank's solution with pH of 7.4, subpackaging in small tubes of 0.5m1, adding 10% SRBC 50 μ l (v/v) prepared by SA solution and 20 μ 1 spleen cell suspension (5 × 10)6Pieces/ml), quickly mixing, pouring onto slide glass brushed with thin layer of agarose, horizontally buckling the slide glass on a slide glass rack after agarose is solidified, placing the slide glass in a carbon dioxide incubator for incubation for 1.5h, and then using the slide glassComplement diluted in SA solution (1: 8) was added to the slide well and the number of lyso-plaques counted after 1.5h of incubation was continued.
2. Results of the experiment
2.1 Effect of the composition on delayed hypersensitivity (DTH) in mice
The influence of the composition on the delayed allergy (DTH) of the mouse is shown in Table 5, and the difference between the influence of the experiment 6 groups on the swelling degree of the foot sole of the mouse and the control group is obvious (P is less than or equal to 0.05), which indicates that the composition for resisting fatigue and improving immunity has the capability of improving the delayed allergy (DTH) of the mouse.
TABLE 5 Effect of compositions on delayed allergy (DTH) in mice
Denotes P ≦ 0.05 with statistical differences compared to the blank group.
2.2 antibody-producing cell assay results
The influence of the composition on the number of mouse antibody-producing cells is shown in Table 6, and the ratio of the influence of the experiment 6 groups on the number of plaques to that of a control group is remarkably different (P is less than or equal to 0.05), so that the composition for resisting fatigue and improving immunity has the capability of increasing the number of mouse antibody-producing cells.
TABLE 6 Effect of compositions on mouse antibody-producing cell number
Denotes P ≦ 0.05 with statistical differences compared to the blank group.
In conclusion, the anti-fatigue and immunity-improving composition can obviously improve the delayed type allergic reaction capability of mice and the number of antibody-producing cells (P is less than or equal to 0.05), and the composition has the function of improving the immunity.
Claims (6)
1. The composition for resisting fatigue and improving immunity is characterized by being prepared from the following components: coenzyme Q10 and grape seed extract;
coenzyme Q10 by mass ratio: grape seed extract ═ 1: 13;
the coenzyme Q10 is reduced coenzyme Q10.
2. A method of preparing the composition of claim 1, comprising: weighing the components according to the proportion, and uniformly mixing to obtain the composition.
3. Use of the composition of claim 1 for the preparation of an anti-fatigue medicament, nutraceutical, beverage or food product.
4. Use of the composition of claim 1 for the preparation of a medicament, health product, beverage or food for enhancing immunity.
5. Use according to claim 3 or 4, wherein the medicament is in a dosage form comprising: tablets, granules, pills, emulsions, granules or capsules; the capsule is soft capsule, hard capsule or microcapsule.
6. Use according to claim 3 or 4, wherein the formulation of the nutraceutical comprises: tablets, granules, pills, emulsions, granules or capsules; the capsule is soft capsule, hard capsule or microcapsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510286099.0A CN104857180B (en) | 2015-05-29 | 2015-05-29 | Composition for resisting fatigue and improving immunity and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510286099.0A CN104857180B (en) | 2015-05-29 | 2015-05-29 | Composition for resisting fatigue and improving immunity and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104857180A CN104857180A (en) | 2015-08-26 |
| CN104857180B true CN104857180B (en) | 2020-02-14 |
Family
ID=53903645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510286099.0A Active CN104857180B (en) | 2015-05-29 | 2015-05-29 | Composition for resisting fatigue and improving immunity and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104857180B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106177227A (en) * | 2016-08-25 | 2016-12-07 | 成都润馨堂药业有限公司 | A kind of compositions containing coenzyme Q10 strengthening body immunity |
| CN110150633A (en) * | 2017-12-25 | 2019-08-23 | 江南大学（如皋）食品生物技术研究所 | Compound anti-oxidation functional food additive and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101322711A (en) * | 2008-01-09 | 2008-12-17 | 济南老来寿生物技术有限公司 | Health care medicament for resisting fatigue and enhancing immunity and preparation thereof |
| CN103300373A (en) * | 2013-06-26 | 2013-09-18 | 重庆艾视生物科技有限公司 | Lutein and procyanidine composite soft capsule and preparation method thereof |
-
2015
- 2015-05-29 CN CN201510286099.0A patent/CN104857180B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101322711A (en) * | 2008-01-09 | 2008-12-17 | 济南老来寿生物技术有限公司 | Health care medicament for resisting fatigue and enhancing immunity and preparation thereof |
| CN103300373A (en) * | 2013-06-26 | 2013-09-18 | 重庆艾视生物科技有限公司 | Lutein and procyanidine composite soft capsule and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104857180A (en) | 2015-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10485836B2 (en) | Anti-fatigue composition used for increasing endurance performance, and use of the same | |
| CN111035649B (en) | NMN + GLP compound nutritional supplement and preparation method and application thereof | |
| CN108042627B (en) | Composition for treating hyperuricemia and preparation method and application thereof | |
| CN101664136A (en) | Method for preparing high-activity nutrient natto and application of high-activity nutrient natto | |
| CN101380346B (en) | Traditional Chinese composition for treating tumor and production method thereof | |
| CN104224885A (en) | Traditional Chinese medicine composition for relieving physical fatigue | |
| CN103564495B (en) | Propolis and cordycepic hypha powder composition, as well as preparation and application thereof | |
| CN105341893A (en) | Composition for assisting in reducing blood glucose and application | |
| CN102526346B (en) | Health-care pharmaceutical formulation with immunity-enhancing and senility-delaying functions | |
| CN104857180B (en) | Composition for resisting fatigue and improving immunity and preparation method and application thereof | |
| CN104922295A (en) | Blood-nourishing and blood-enriching traditional Chinese medicine composition | |
| CN102657730A (en) | Rhodiola rosea buccal preparations for resisting altitude reaction | |
| US9943560B2 (en) | Medical compositions containing liquorice extracts with synergistic effect | |
| CN112494626B (en) | Tablet with protective effect on chemical liver injury and preparation method thereof | |
| KR20150031373A (en) | Phamaceutical and food composition for preventing or treating obesity comprising extract of leaf from Hoppophea rhamnoids as effective component | |
| TWI612968B (en) | A use of an extract of asplenium australasicum (j. sm.) hook. | |
| CN109394799B (en) | Natural pharmaceutical composition containing ganoderma lucidum extract and preparation method and application thereof | |
| CN106822338A (en) | Compound of reducing blood sugar and blood fat, prevention and/or treatment diabetes and its complication and application thereof | |
| CN102973585B (en) | Application of gentiopicroside in treatment of hyperuricemia | |
| KR101093006B1 (en) | Method for producing functional health food containing bezoar bovis used microbes and the functional health food produced by the same | |
| CN101032534A (en) | Method of preparing jiubiying total saponins and the application thereof | |
| CN106511401A (en) | Preparation method and application of cordyceps taii mycelia polysaccharides | |
| CN104258034A (en) | Traditional Chinese medicine composition for boosting immunity | |
| CN106924329B (en) | Application of Aidi preparation in preparation of medicine for treating malignant trophoblastic tumor | |
| CN104352672A (en) | Tortoise plastron-containing traditional Chinese medicine composition for treating diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |